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  This study was performed to evaluate the osteogenic effect of 
allogenic  canine  umbilical  cord  blood-derived  mesenchymal 
stem cells (UCB-MSCs) mixed with beta-tricalcium phosphate 
(β-TCP) in orthotopic implantation. Seven hundred milli-
grams of β-TCP mixed with 1 × 10
6 UCB-MSCs diluted with 
0.5 ml of saline (group CM) and mixed with the same volume 
of saline as control (group C) were implanted into a 1.5 cm 
diaphyseal defect and wrapped with PLGC membrane in the 
radius of Beagle dogs. Radiographs of the antebrachium 
were made after surgery. The implants were harvested 12 
weeks after implantation and specimens were stained with 
H&E,  toluidine  blue  and  Villanueva-Goldner  stains  for 
histological examination and histomorphometric analysis of 
new bone formation. Additionally, UCB-MSCs were applied 
to a dog with non-union fracture. Radiographically, continuity 
between implant and host bone was evident at only one of six 
interfaces in group C by 12 weeks, but in three of six interfaces 
in group CM. Radiolucency was found only near the bone 
end in group C at 12 weeks after implantation, but in the 
entire graft in group CM. Histologically, bone formation 
was  observed  around  β-TCP  in  longitudinal  sections  of 
implant in both groups. Histomorphometric analysis revealed 
significantly increased new bone formation in group CM at 
12 weeks after implantation (p ＜ 0.05). When applied to the 
non-union fracture, fracture healing was identified by 6 
weeks  after  injection  of  UCB-MSCs.  The  present  study 
indicates  that  a  mixture of  UCB-MSCs and  β-TCP is  a 
promising osteogenic material for repairing bone defects.
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Introduction 
  Repairing non-union fractures or bony defects is surgically 
challenging. Synthetic bone substitutes and osteogenic 
materials have been evaluated as aids [2,18,29,31]. Among 
the synthetic bone substitutes, hydroxyapatite and other 
calcium phosphate ceramics have shown the most promising 
results due to their osteoconductive properties, unlimited 
availability and absence of immune response [9,25,28]. A 
potential limitation of such materials is the slow 
biodegradation rate observed in pure hydroxyapatite. 
However, implants comprised of beta-tricalcium phosphate 
(β-TCP) are resorbable [6]. β-TCP has shown good 
biocompatibility and osseointegration, but appreciable 
amounts were still present after 12 months [17]. 
  Recently, it has been reported that umbilical cord blood 
can serve as an alternative source of mesenchymal stem 
cells (MSCs), and human umbilical cord blood-derived 
MSCs (UCB-MSCs) contain multi-potent cells including 
those with osteogenic potential [22,27]. Furthermore, 
UCB-MSCs may be immune-privileged cells with surface 
characteristics that enable circumvention of immune 
rejection [5,7]. Recently, we isolated canine UCB-MSCs 
[21], which provides a ready source of the cells.
  The present study reports enhanced osteogenesis by the 
implantation of canine UCB-MSCs mixed with β-TCP in 
bone defect model dogs, and the successful repair of a 
non-union fracture case by allografting and injection of 
canine UCB-MSCs.
Materials and Methods
Animals
  Six healthy Beagle dogs (15.4 ± 1.2 months, B.W 6∼ 7 kg) 
were used for the orthotopic implantation. There were two 388    Byung-Jun Jang et al.
Fig. 1. Radiographs of antebrachium in clinical application. (A) 
Preoperative: non-union fracture of the right distal radius. (B) 
Postoperative: plate & screw fixation with cortical allograft and
cancellous bone autograft. (C) 9 weeks postoperative: Bone lysis,
irregular margin and disuse atrophy of the bone were observed.
experimental groups: canine UCB-MSCs grafting and 
control, with three dogs per group. The dogs were housed 
in indoor cages. Food and water were supplied ad libitum. 
All animal experiments conformed to the Guidelines for 
Animal Experiments of Seoul National University.
Preparation of canine UCB-MSCs
  Fetal umbilical cord blood was collected during Caesarean 
section of pregnant female dogs. Canine UCB-MSCs were 
produced by culturing to facilitate proliferation of 
mononucleated cells from cord blood as verified by 
fluorescence-activated cell sorting (FACS) analysis, and by 
the in vitro differentiation of bone [21]. Cells (1 × 10
6) were 
prepared for implantation. Canine UCB-MSCs were 
suspended with 500 μl of normal saline prior to mixing with 
700 mg of β-TCP (group CM). The same volume of normal 
saline mixed with β-TCP was prepared as the control (group C).
Bioceramic implants
  β-TCP powder and the β-TCP/poly L-lactide-co-ε-caprolactone 
composite (TCP/PLGC) membrane were gifts of the 
Biomaterials Center, National Institute for Materials 
Science, Japan. β-TCP particle diameter averaged about 
125 μm and the molecular weight of PLGC was 250,000. 
Each TCP/PLGC membrane was prepared by mixing β-TCP 
particles and PLGC in a weight ratio of 7：3 for 10 min at 
180
oC. The composite was formed into 200 μm thick 
membranes with a hot-press [15].
Orthotopic implantation and harvest
  After dogs were premedicated with 0.2 mg butorphanol 
(Myungmoon Pharm, Korea) at a dose of 0.2 mg/kg body 
weight and acepromazine maleate (Samwoo, Korea) at a 
dose of 0.05 mg/kg body weight, 1% propofol (Claris 
Lifesciences, India) at a dose of 6 mg/kg body weight was 
intravenously injected to induce anesthesia. Isoflurane 
(Ilsung Pharmaceutical, Korea) was used to maintain 
anesthesia. Under sterile conditions, a craniomedial approach 
was performed to expose the diaphysis of right radius. The 
periosteum was elevated only enough to allow the plate to 
lie directly on the bone. An eight-hole, 2.7 dynamic 
compression plate (Synthes, Switzerland) was contoured 
and applied to the cranial aspect of the radius. The plate was 
then removed and a 15 mm long osteoperiosteal segmental 
cortical defect was made at the mid-portion of the diaphysis 
with an oscillation bone saw [3]. The plate was then 
reapplied, mixed materials were implanted in the defect, and 
the implanted site was wrapped with TCP/PLGC to prevent 
leakage of implants. After closing the soft tissue, a Robert 
John’s bandage was applied for 2 weeks. The implants were 
harvested 12 weeks after implantation.
Radiographic examination 
    Lateral and craniocaudal radiographs of the right 
antebrachium were made before and immediately after 
surgery as well as 2, 4, 8 and 12 weeks after implantation. 
Each radiographic evaluation focused on the continuity 
between host bone and implant, and the change of implant 
radiopacity.
Histological examination
  Segments of bone including defect sites were removed 
and processed for histological analysis without decalcification. 
Specimens were fixed in 4% paraformaldehyde and 
processed for methyl methacrylate embedding using an 
Osteo-Bed Bone embedding kit (Polysciences, USA). 
Longitudinal sections were cut in the sagittal planes using 
a microtome. The central longitudinal sections from each 
radius were ground to a thickness of 100 μm and stained 
with hematoxylin and eosin (H&E), toluidine blue, and 
Villanueva-Goldner stains to evaluate new bone formation. 
Stained sections from each group were observed under a 
light microscope and were scanned using an attached 
digital camera and a NIS-Elements system (Nikon, Japan). 
The areas of new bone formation and the residual β-TCP 
were determined and converted to a percentage of total 
area of bone defect.
Statistics
  Student's t-test was performed to compare the new bone 
formation between the C and CM groups at a 95% 
confidence level. 
Clinical application
  A 6-month-old Toy poodle that had been operated on twice 
previously presented to the Veterinary Medical Teaching Bone defect stem cell repair    389
Fig. 2. Lateral radiographs of antebrachium after implantation and 2, 4, 8, 12 weeks. Radiolucency is found only near bone end in group
C (implantation of β-TCP with saline), but entire graft in group CM (implantation of β-TCP with umbilical cord blood derived stem 
cells) at 12 weeks.
Hospital, Seoul National University, with radial non-union 
fracture (Fig. 1A). A cortical allograft was implanted (Fig. 
1B). Graft lysis and instability of fractured site were observed 
9 weeks after implantation (Fig. 1C). Under fluoroscopy-aided 
guidance, 1 × 10
7 canine UCB- MSCs diluted with 0.5 ml 
saline were injected into the bone defect formed by graft 
lysis. Another injection was done 1 month later.
Results
Animal model
  All dogs were able to bear weight partially by 2 weeks, 
after which they became active in their enclosures. All 
wounds healed without infection and there were no failures 
of fixation.
Radiographic findings
    Postoperatively, the defect could be visualized easily 
because of the radiopacity of the material. With time, the 
radiolucent site gradually expanded from interface between 
the host bone and the implant to the central part of the defect 
in both groups, but the tendency was clearer in group CM 
(Fig. 2). Radiolucency was found only near the bone end in 
group C by 12 weeks but was evident throughout the entire 
graft in group CM. 
  Union between implant and host bone was seen at only 
one of six interfaces in group C by 12 weeks (Fig. 2: 
proximal interface of C1). In group CM, continuity was 
established at three of six interfaces by 12 weeks (Fig. 2: 
proximal interface of CM1, 2 and 3).
Histological findings
  Bone formation was observed around β-TCP in longitudinal 390    Byung-Jun Jang et al.
Fig. 4. Microphotographs of implants at 12 weeks after implantation in the group CM.  New bone was in direct contact with the β-TCP
granules.  (A) H&E stain: Osteocyte is observed around the β-TCP. (B) Villanueva-Goldner stain (red-immature bone, green-mature 
bone). (C) Toluidine blue stain.
Fig. 3. Microphotographs of longitudinal sections of implants in 
the groups C (A) and CM (B, C) at 12 weeks after implantation of
β-TCP. The proximal portion is at the top of the photomicrograph.
The cranial aspect of bone (where the fixation plate had been) is
at the left of photomicrograph. Bone appears blue or red, and 
ceramic appears black. (A, B) toluidine blue stain. (C) Villanueva- 
Goldner stain. ×10. Bone formation is observed around β-TCP 
throughout the implant. β-TCP remained in both side of the 
implant, especially under fixation plate and in the group C.
sections of implants in both groups 12 weeks after 
implantation (Fig. 3). β-TCP remained in both sides and the 
distal one third of the implant, especially under the fixation 
plate and in group C. Osteocytes were evident around the 
β-TCP (Fig. 4A). New bone was in direct contact with the 
β-TCP granules (Figs. 4B and C). Histomorphometric 
analysis revealed percentages of new bone formation in 
groups C and CM were 4.08 ± 2.08 and 10.92 ± 2.74, 
respectively (p ＜ 0.05). Residual percentages of β-TCP 
were 40.63 ± 17.86 and 24.21 ± 8.75, in groups C and CM, 
respectively (Table 1). 
Clinical application
  Radiographically, increased opacity between radius and 
allograft bone, and a decreased radiolucent gap was checked 
four weeks after injection of canine UCB-MSCs. With time, 
the radiolucent site gradually decreased and the radiolucent 
fracture line disappeared (Fig. 5). Instability at fracture site Bone defect stem cell repair    391
Fig. 5. Lateral radiographs of antebrachium at 0, 4, 8, and 12 
weeks after first injection of canine umbilical cord blood derived 
stem cells.
Table 1. Histomorphometric analysis 
Group NBA/TA (%) RTA/TA (%)
C
CM
   4.08 ± 2.08
a  
  10.92 ± 2.74*
  40.63 ± 17.86
24.21 ± 8.75
NBA: new bone formation area. RTA: residual β-TCP area. TA: total
area. *p ＜ 0.05 compared with C group. 
aAll values are means ± SD.
was decreased by 8 weeks after injection. The dog could 
bear weight partially by 8 weeks.
Discussion
  Radiography is useful to assess the union at host bone- 
implant interfaces as an important factor of bone healing 
[1,3]. Presently, a distinct radiolucent zone at the interface 
between implants and the host bone was visible on the 
immediate postoperative radiographs. The absence of this 
radiolucent zone was considered to be an indication of 
union between the implant and the host bone. In the present 
study, union at the host bone-implant interface occurred 
more often and more rapidly in group CM than group C. An 
ideal bone graft substitute should resorb fully and at a 
predictable rate, while also providing a three-dimensional 
matrix to support bone ingrowth and ongrowth during 
resorption [33]. The appearance of implanted β-TCP on 
X-rays was the density of bone in early phase. Thereafter, 
as further resorption of the β-TCP and bone remodeling 
occurred, density decreased more [32]. In this study, 
radiolucency was found only near the bone end in group C, 
but throughout the entire graft in group CM at 12 weeks. 
  Previous studies used bloc ceramics with pores precultured 
with cells in osteogenic medium or vacuumed for uniform 
loading and retention of cells [13,34]. In the present study, 
β-TCP granules were mixed with cells immediately before 
implantation; this method of cell-matrix combination can 
be easily performed in a clinical setting. 
  In  the  previous  report  [3], new bone was distributed 
uniformly throughout the cell-matrix implant. However, in 
the present study, β-TCP remained in both sides and the 
distal one third of the implant, especially under the fixation 
plate and in group C, as evident histologically 12 weeks 
after implantation. β-TCP that remained under the fixation 
plate could be due to impaired blood supply to outer 
cortical bone beneath plates [8]. In the present study, 
implants were wrapped with TCP/PLGC membrane to 
prevent leakage of the β-TCP granule-cell mixture and 
invasion of fibrous connective tissues into the implant 
instead of vascular and host bone ingrowth. In assessing 
the present observations, it was suggested that vascular or 
bone ingrowth may have depended largely on proximal 
host bone. Bone formation with bone graft substitute relies 
on a complex sequence of events with a major dependence 
on vascular ingrowth, differentiation of osteoprogenitor 
cells, bone remodeling and graft resorption that occur 
together with host bone ingrowth into and onto the porous 
coralline microstructure or voids left behind during 
resorption [33]. Callus formation around an implant in the 
segmental defect treated with a ceramic cylinder that had 
been loaded with mesenchymal stem cells was reported 
[3]; similar observations were not made in the present 
study. It is conceivable that TCP/PLGC membrane might 
interrupt vascular ingrowth around implant and callus 
formation. 
  Histomorphological examinations conducted 12 weeks 
after the implantation of mixture of β-TCP and cells 
revealed significantly greater area of new bone formation 
than control (p ＜ 0.05) and a smaller amount of residual 
TCP. Previous studies showed that bone marrow-derived 
MSCs are capable of forming bone in vitro [12,13], and 
when implanted in an appropriate matrix ectopically or 
orthotopically [3,14]. Implants with autologous bone 
marrow MSCs contain more new bones within and around 
implants in canine segmental bone defect [3]. While 
undifferentiated adipose derived stromal cells with β-TCP 
does not affect bone regeneration [20], canine UCB-MSCs 
presently produced a contrary result. 
  In a study involving athymic rats, human UCB-MSCs 
displayed osteogenic differentiation in vitro, survived after 
xenotransplantation and differentiated into osteoblasts that 
filled the bony defects [10]. A recent study reported that 
human UCB-MSCs have a significantly stronger osteogenic 
potential but less capacity in adipogenic differentiation than 
bone marrow MSCs in vitro [4]. Presently, canine UCB- 
MSCs might have enhanced new bone formation by 
differentiating to osteoblast progenitors. Alternatively, a 
paracrine effect of canine UCB-MSCs may have enhanced 
new bone formation. Analyses of bone marrow MSCs with 
real-time polymerase chain reaction and of bone marrow 
MSC-conditioned medium by antibody-based protein array 392    Byung-Jun Jang et al.
and enzyme-linked immunosorbant assay indicated that 
bone marrow MSCs secrete distinctively different cytokines 
and chemokines such as vascular endothelial growth factor 
(VEGF), insulin-like growth factor-1, epidermal growth 
factor, keratinocyte growth factor, angiopoietin-1, stromal 
derived factor-1, macrophage inflammatory protein-1alpha, 
-1beta and erythropoietin, compared to dermal fibroblasts 
[5]. Several cytokines, chemokines and growth factors are 
produced during in vitro osteogenic differentiation from 
human UCB-MSCs, with VEGF being perhaps the most 
critical driver of vascular formation during osteogenesis 
[26]. VEGF also stimulates osteoblast proliferation, migration 
and differentiation [23]. These cytokine alterations accelerate 
osteogenesis [16,19,30,35]. Further studies will be needed 
to elucidate the mechanism of bone formation by canine 
UCB-MSCs. 
  In a cortical allograft, the host-graft interface heals within 
3 months [11]. Vascular invasion begins at the interface 
and progresses toward the center of the graft. Remodeling 
of the graft takes months to years, depending on the length, 
and might never be complete [24]. In the present clinical 
case, bone lysis and instability of the fractured site was 
evident by 9 weeks after cortical allograft. After injection 
of canine UCB-MSCs, bone regeneration gradually appeared 
in defect sites. Although there was some doubt whether 
bone formation was attributable to the introduced canine 
UCB-MSCs or to an endochondral sequence, the injected 
canine UCB-MSCs injected might play a role in 
osteoconduction in the graft site.
  The results of the present study demonstrate that canine 
UCB-MSCs accelerate new bone formation upon the 
implantation of β-TCP into segmental defects in dogs. 
Implantation of allogenic UCB-MSCs with β-TCP holds 
promise in the clinical repair of segmental bone defects and 
non-union fractures.
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